| EPZ020411 |
EPZ020411 盐酸盐的形式 |
1700663-41-7 |
| BET-BAY-002 |
1588521-78-1 |
1588521-78-1 |
| AZD3264 |
AZD3264 |
1609281-86-8 |
| HA-15 |
HA-15 |
1609402-14-3 |
| BAY-1217389 |
CS-2361 |
1554458-53-5 |
| N-(3-((2-((3-Fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)phenyl)acrylamide maleate |
N-(3-((2-((3-氟-4-(4-甲基哌嗪-1-基)苯基)氨基)-7H-吡咯并[2,3-D]嘧啶-4-基)氧基)苯基)丙烯酰胺酸盐 |
1557268-88-8 |
| 9-(6-Amino-3-pyridinyl)-1-[4-fluoro-3-(trifluoromethyl)phenyl]benzo[h]-1,6-naphthyridin-2(1H)-one |
9-(6-氨基-3-吡啶基)-1-[4-氟-3-(三氟甲基)苯基]苯并[H]-1,6-萘啶-2(1H)-酮 |
1223002-54-7 |
| OTSSP167HCL |
OTSSP 167 盐酸盐 |
1431698-10-0 |
| FRAX1036 |
FRAX1036 |
1432908-05-8 |
| NVP-TNKS656 |
NVP-TNKS656 |
1419949-20-4 |
| PTC-209 (hydrobroMide) |
PTC-209HBR |
1217022-63-3 |
| GSK 2830371 |
GSK 2830371 |
1404456-53-6 |
| GSK J2 |
N-[2-(3-吡啶基)-6-(1,2,4,5-四氢-3H-3-苯并氮杂卓-3-基)-4-嘧啶基]-BETA-丙氨酸 |
1394854-52-4 |
| AM-679 |
AM-679 |
1206880-66-1 |
| AMG 232 |
2-((3R,5R,6S)-5-(3-氯苯基)-6-(4-氯苯基)-1-((S)-1-(异丙基磺酰基)-3-甲基丁烷-2-基)-3-甲基-2-氧代哌啶-3-基)乙酸 |
1352066-68-2 |
| NMS-P715 |
NMS-P715 |
1202055-34-2 |
| AC710 |
N-[4-[[[[5-(叔丁基)-3-异恶唑基]氨基]羰基]氨基]苯基]-5-[(1-乙基-2,2,6,6-四甲基-4-哌啶基)氧基]-2-吡啶甲酰胺 |
1351522-04-7 |
| LDN-211904 |
N-(2-氯苯基)-6-(4-哌啶基)-咪唑并[1,2-A]吡啶-3-甲酰胺 |
1198408-39-7 |
| ATI-2341 |
变构激动剂多肽ATI 2341 |
1337878-62-2 |
| BP-1-102 |
4-(N-(4-环己基苄基)-2-((2,3,4,5,6-五氟-N-甲苯基)磺酰氨基)乙酰氨基)-2-羟基苯甲酸 |
1334493-07-0 |
